Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Oral NX-13 for Patients with Moderate to Severe Ulcerative Colitis

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Ulcerative Colitis, a condition that causes inflammation and sores in the digestive tract. The treatment being tested is called NX-13, which is taken as a tablet. The study will compare the effects of NX-13 with a placebo to understand its clinical activity and safety in people with moderate to severe forms of this disease.

The purpose of the study is to evaluate how well NX-13 works and how safe it is for participants. The study will involve multiple doses and will be conducted over a period of time, allowing researchers to observe any changes in the condition of the participants. Participants will be randomly assigned to receive either the NX-13 tablets or a placebo, and neither the participants nor the researchers will know who is receiving which treatment during the study.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects. The study aims to provide valuable information on the potential benefits and risks of using NX-13 as a treatment for Ulcerative Colitis, contributing to the development of new therapies for this condition.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit and consent

    Upon joining the study, you will attend an initial visit where you will be asked to provide informed consent. This means you agree to participate in the study after understanding all the details, risks, and benefits.

    During this visit, your eligibility will be confirmed based on criteria such as age, medical history, and current health status.

  2. Step 2

    Screening procedures

    You will undergo various screening procedures to ensure you meet the study requirements. This may include a colonoscopy to confirm the diagnosis of ulcerative colitis and rule out other conditions.

    Additional tests may include blood tests and a review of your medical history.

  3. Step 3

    Randomization and treatment assignment

    Once you pass the screening, you will be randomly assigned to receive either the study medication NX-13 or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

    This process is double-blind, meaning neither you nor the study team will know which treatment you are receiving.

  4. Step 4

    Treatment phase

    You will take the assigned treatment orally in the form of a tablet. The dosage and frequency will be provided by the study team.

    This phase will last for a specified period, during which you will be required to attend regular study visits and complete e-diaries to monitor your health and any symptoms.

  5. Step 5

    Follow-up visits

    Throughout the study, you will have scheduled follow-up visits to assess your health and the effects of the treatment.

    These visits will include physical examinations, laboratory tests, and possibly additional colonoscopies to evaluate the condition of your ulcerative colitis.

  6. Step 6

    End of treatment and extension phase

    At the end of the initial treatment period, your response to the medication will be evaluated.

    If eligible, you may enter a long-term extension phase where you continue to receive the study medication and attend regular follow-up visits.

  7. Step 7

    Study completion

    Upon completing the study, you will have a final visit to assess your overall health and gather any remaining data.

    You will be informed about the next steps and any additional follow-up that may be necessary.

Who can join the trial?

18 criteria

  • Must be between 18 to 75 years old at the time of giving consent.
  • Women of childbearing potential must agree to use highly effective birth control methods, such as:
    • Combined hormonal contraception (oral, intravaginal, transdermal)
    • Progestogen-only hormonal contraception (oral, injectable, implantable)
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion (blocking of fallopian tubes)
    • Partner with a vasectomy
    • Sexual abstinence
    • Must be able to give informed consent and attend study visits.
    • Must have been diagnosed with Ulcerative Colitis (UC) for at least 3 months before screening, confirmed by specific medical tests.
    • Must have had a colonoscopy within 12 months before the study to check for abnormal growths in the colon if they have had certain types of colitis for a long time. If not, a colonoscopy will be done during screening.
    • Must have moderate to severe disease activity, as defined by specific medical criteria.
    • Must have had an inadequate response, loss of response, or intolerance to at least one of the following treatments:
      • Conventional therapies like oral 5-ASA compounds and systemic glucocorticosteroids
      • Biologic therapies like anti-TNF, anti-integrin, or anti-IL-12/23 monoclonal antibodies
      • Advanced therapies like JAK inhibitors or S1P receptor modulators
      • Eligible male participants must either be surgically sterile (vasectomy) for at least 3 months before screening or agree to use a condom with spermicide and not try to conceive for at least 30 days after the last dose of the study medication.
      • Eligible female participants must be nonpregnant, confirmed by a pregnancy test, and not breastfeeding.
      • Female participants who cannot have children must be surgically sterile or postmenopausal (no menstrual periods for at least 1 year).

Who cannot join the trial?

10 criteria

  • Patients who have a history of severe allergic reactions to any of the ingredients in the study medication cannot participate.
  • Patients with other significant health conditions that might interfere with the study results are not eligible.
  • Pregnant or breastfeeding women are excluded from the study.
  • Patients who have participated in another clinical trial within the last 30 days are not allowed to join.
  • Individuals with a history of substance abuse or addiction may not participate.
  • Patients who are unable to comply with the study procedures or follow-up visits are not eligible.
  • Anyone who has had a major surgery within the last 3 months is excluded.
  • Patients with a history of certain infections, such as tuberculosis, are not eligible.
  • Individuals with a compromised immune system, which means their body's defense against infections is weakened, cannot participate.
  • Patients who are currently taking medications that might interfere with the study drug are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

NX-13 is an experimental medication being tested for its potential to help people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. This medication is taken by mouth and is designed to reduce inflammation in the digestive tract, which may help alleviate symptoms like abdominal pain and diarrhea. The study aims to see how well NX-13 works in improving the condition and to ensure it is safe for long-term use.

What is already known about the treatment

NX-13 – NX-13 is an oral medication currently being studied in clinical trials for its potential to treat moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. The medication is taken by mouth, and researchers are investigating its effectiveness and safety compared to a placebo. NX-13 works by targeting specific pathways in the immune system to reduce inflammation at the molecular level. It is classified as an investigational drug, meaning it is still being tested and is not yet approved for general medical use.

Investigated diseases

Ulcerative Colitis – Ulcerative Colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by inflammation and ulceration of the innermost lining of the large intestine. The disease typically begins in the rectum and may extend continuously to involve the entire colon. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The inflammation can lead to frequent and urgent bowel movements. Over time, the disease can cause complications such as severe bleeding or perforation of the colon.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-503005-38-00Protocol codeNX-13-201/M25-484Estimated enrolment97 patientsSponsorLandos Biopharma Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.